The theme of this annual, “Stronger every day,” reflects Dendreon’s efforts to help advanced-state prostate cancer patients live longer, fuller lives—as well as the milestone achieved when the company’s lead product, PROVENGE®, became the first cancer immunotherapy treatment to be reviewed by the FDA for a Biologics License Application. It was a privilege to work with patients, physicians, employees and management in conveying the importance of this year to Dendreon’s stakeholders.

> View PDF